Looking to move past an R&D fiasco, Ipsen poaches their new CEO from Sanofi
Ipsen has turned to another Paris-based biopharma company for its next CEO.
Sanofi Pasteur chief David Loew — who’s been leading one of the most advanced efforts to develop vaccines for Covid-19 — is making the journey to Ipsen, 5 months after David Meek jumped ship to run a startup in late-stage development.
Loew arrives as Ipsen works to get back on track with their rare bone disease drug palovarotene, picked up in the $1.3 billion Clementia buyout, which was slammed with a partial hold after researchers observed cases of “early growth plate closure” in patients under the age of 14. But they are pushing ahead with the over-14 crowd after writing down slightly more than half of its initial development.
Loew has been running the show at Sanofi Pasteur for the past 4 years after building a career that started at Coopers & Lybrand and Hewlett Packard in 1990, He jumped to biopharma by joining Roche in 1992, then rose through the commercial ranks before leaping to Sanofi in 2013, running the European commercial ops.
Ipsen’s sales revenue topped €2.5 billion last year, based on a portfolio including more than 20 drugs.